Cidara Therapeutics, Inc. (CDTX)

Market Cap	56.06M
Revenue (ttm)	63.91M
Net Income (ttm)	-22.93M
Shares Out	4.56M
EPS (ttm)	-0.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	57,748
Open	10.18
Previous Close	10.25
Day's Range	10.11 - 12.59
52-Week Range	10.00 - 29.60
Beta	1.01
Analysts	Strong Buy
Price Target	4.50 (-63.38%)
Earnings Date	Apr 22, 2024

About CDTX

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 15, 2015
• Employees: 73
• Stock Exchange: NASDAQ
• Ticker Symbol: CDTX

Financial Performance

In 2023, CDTX's revenue was $63.91 million, a decrease of -0.84% compared to the previous year's $64.45 million. Losses were -$22.93 million, -31.72% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for CDTX stock is "Strong Buy." The 12-month stock price forecast is $4.5, which is a decrease of -63.38% from the latest price.

Price Target

$4.5

(-63.38% downside)

Analyst Consensus: Strong Buy